Cargando…

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis

BACKGROUND: Abatacept (ABA) is a biological disease-modifying antirheumatic drug (bDMARD) for rheumatoid arthritis (RA). The aim of this study was to identify molecules that are associated with therapeutic responses to ABA in patients with RA. METHODS: Peripheral blood was collected using a PAX gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokoyama-Kokuryo, Waka, Yamazaki, Hayato, Takeuchi, Tsutomu, Amano, Koichi, Kikuchi, Jun, Kondo, Tsuneo, Nakamura, Seiji, Sakai, Ryoko, Hirano, Fumio, Nanki, Toshihiro, Koike, Ryuji, Harigai, Masayoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068901/ https://www.ncbi.nlm.nih.gov/pubmed/32164778 http://dx.doi.org/10.1186/s13075-020-2137-y

Ejemplares similares

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2021)

An open-label, randomized controlled trial of sulfamethoxazole–trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up
por: Utsunomiya, Masako, et al.
Publicado: (2020)

Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial
por: Utsunomiya, Masako, et al.
Publicado: (2017)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis
por: Fukuda, Shin, et al.
Publicado: (2014)

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
por: Sakai, Ryoko, et al.
Publicado: (2015)

Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid–lysophosphatidic acid receptor 1 cascade
por: Miyabe, Yoshishige, et al.
Publicado: (2014)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study
por: Matsubara, Tsukasa, et al.
Publicado: (2018)

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
por: Koike, Ryuji, et al.
Publicado: (2009)

Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study
por: Sakai, Ryoko, et al.
Publicado: (2022)

Tocilizumab monotherapy uncovered the role of the CCL22/17‐CCR4(+) Treg axis during remission of crescentic glomerulonephritis
por: Sakai, Ryota, et al.
Publicado: (2020)

Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study
por: Hirose, Wataru, et al.
Publicado: (2015)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
por: Koike, Takao, et al.
Publicado: (2011)

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data
por: Tanaka, Eiichi, et al.
Publicado: (2022)

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice
por: Yokoyama, Waka, et al.
Publicado: (2014)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Application of MALDI-TOF MS to assess clinical characteristics, risk factors, and outcomes associated with anaerobic bloodstream infection: a retrospective observational study
por: Watanabe, Tsuyoshi, et al.
Publicado: (2021)

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
por: Okuyama, Ayumi, et al.
Publicado: (2010)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
por: Takeuchi, Tsutomu, et al.
Publicado: (2013)

Concurrent Takayasu Arteritis and Vascular Ehlers–Danlos Syndrome: A Case Report
por: Hashimoto, Kyota, et al.
Publicado: (2022)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Development of Rheumatoid Arthritis in Cavitary Mycobacterium avium Pulmonary Disease: A Case Report of Successful Treatment with CTLA4-Ig (Abatacept)
por: Tanaka, Hiromu, et al.
Publicado: (2022)

Fatal and extensive multiorgan hemorrhages in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: An autopsy case report
por: Watanabe, Tsuyoshi, et al.
Publicado: (2020)

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
por: Takahashi, Nobunori, et al.
Publicado: (2013)

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
por: Takeuchi, Tsutomu, et al.
Publicado: (2018)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ks0pg32micov1mfq9bvsisjjr